Jefferies Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Jefferies Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Buy	+18,100	New	+$89.3K	﹤0.01%	1531

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jefferies Financial Group's IMDX Position: Q2 2026 in Review

Jefferies Financial Group opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 18,100 shares worth $107K. The stake represents ﹤0.01% of the portfolio and ranks #1531 among its holdings.

40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Jefferies Financial Group held 18,100 shares of Insight Molecular Diagnostics worth $107K as of Q2 2026.
Insight Molecular Diagnostics was a new Jefferies Financial Group position in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1531 holding.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.